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Causes of non-adherence to therapeutic guidelines 
in severe community-acquired pneumonia
ORIGINAL ARTICLE
INTRODUCTION
Acute respiratory infection is associated with high morbidity and social 
costs,(1,2) which significantly increase in complicated cases with septic shock.(3,4) 
Antibiotic therapy is one of the most effective tools for reducing mortality.(4) 
The association between the administration of inadequate antibiotics in the case 
of respiratory septic shock and a significant increase in both morbimortality(5-7) 
and multi-drug resistance has been extensively described.(8)
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Objective: To assess the adherence to 
Infectious Disease Society of America/
American Thoracic Society guidelines 
and the causes of lack of adherence 
during empirical antibiotic prescription 
in severe pneumonia in Latin America.
Methods: A clinical questionnaire 
was submitted to 36 physicians from 
Latin America; they were asked to indicate 
the empirical treatment in two fictitious 
cases of severe respiratory infection: 
community-acquired pneumonia and 
nosocomial pneumonia.
Results: In the case of community-
acquired pneumonia, 11 prescriptions 
of 36 (30.6%) were compliant with 
international guidelines. The causes 
for non-compliant treatment were 
monotherapy (16.0%), the unnecessary 
prescription of broad-spectrum antibiotics 
(40.0%) and the use of non-recommended 
antibiotics (44.0%).
In the case of nosocomial pneumonia, 
the rate of adherence to the Infectious 
Disease Society of America/American 
Thoracic Society guidelines was 2.8% 
(1 patient of 36). The reasons for lack of 
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Advance directive adherence
compliance were monotherapy (14.3%) 
and a lack of dual antibiotic coverage 
against Pseudomonas aeruginosa (85.7%). 
If monotherapy with an antipseudomonal 
antibiotic was considered adequate, the 
antibiotic treatment would be adequate 
in 100% of the total prescriptions.
Conclusion: The compliance rate 
with the Infectious Disease Society of 
America/American Thoracic Society 
guidelines in the community-acquired 
pneumonia scenario was 30.6%; the 
most frequent cause of lack of compliance 
was the indication of monotherapy. In 
the case of nosocomial pneumonia, the 
compliance rate with the guidelines was 
2.8%, and the most important cause of 
non-adherence was lack of combined 
antipseudomonal therapy. If the use of 
monotherapy with an antipseudomonal 
antibiotic was considered the correct 
option, the treatment would be adequate 
in 100% of the prescriptions.
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Several scientific societies have published therapeutic 
and clinical management recommendations, with the 
guidelines published by the Infectious Disease Society of 
America/American Thoracic Society (IDSA/ATS) serving 
as a reference in Latin America.(9,10)
Various studies conducted in Europe,(11,12) the United 
States(13) and Australia(14) have analyzed adherence to 
therapeutic guidelines in empirical antibiotic prescription. 
However, no similar studies have been performed in Latin 
America.
In the present study, adherence to IDSA/ATS 
indications for the treatment of severe pneumonia and 
the causes of non-compliance with the recommendations 
were analyzed.
METHODS
A survey was administered to 36 Latin American 
physicians with extensive experience in the intensive care 
unit (ICU). The survey was administered during a course 
on antibiotic politics for critical care patients, which took 
place in the Hospital Vall d’ Hebron, Barcelona, Spain, in 
May and July of 2013. The same questionnaire was utilized 
to conduct an Australian study published by Dulhunty 
et al.(14) and is composed of fictitious clinical cases of patients 
with severe infection. In the present study, only cases of 
respiratory infection were analyzed: community-acquired 
pneumonia and nosocomial pneumonia. Both settings are 
described in the electronic supplementary materials.
All participants were asked to indicate their medical 
specialty, their years of experience in the ICU and the 
characteristics of the hospital/ICU at which they worked. 
In addition, for each clinical case, they were requested 
to indicate how many and which antibiotics they would 
prescribe, their dose and duration. For these cases, the 
presence of empyema or any other complication that 
required surgical intervention or an invasive procedure 
was discarded. The weight of the patient was indicated as 
being 80kg, and their renal and liver function was listed 
as normal.
They were asked to choose between one and three 
antibiotics without including antivirals, antifungals 
or tuberculostatic drugs. The dose of medication was 
calculated and expressed in g per day.
The two settings were bilateral community-acquired 
pneumonia with secondary septic shock (case 1, 
available in the electronic supplementary materials); 
and nosocomial pneumonia in the postoperative period 
following cholecystectomy (case 2, available in the 
electronic supplementary materials).
The number of antibiotics indicated, along with their 
dose and duration, was recorded. The indicated regimen 
and the dose of antibiotic were then consulted according 
to the indications from the respective therapeutic guides. 
As specific indications for Latin America did not exist, we 
decided to utilize the IDSA/ATS recommendations.(9,10) 
In table S1 of the electronic supplementary materials, the 
recommended antibiotic regimens are indicated. In the 
case of prescription of antibiotics that were not indicated 
in the recommendations or where the dose of antibiotic 
established by the IDSA/ATS was omitted, the dose 
suggested by the manuals with the greatest frequency of 
clinical use was considered to be valid.(15)
Because this was a spontaneous survey conducted using 
fictitious clinical cases, informed consent was not solicited 
to perform this study. The survey participants were 
informed about the purpose of the survey and notified 
that their compliance was not a condition for obtaining 
the certificate of course participation.
The results are expressed as the medians and interquartile 
ranges for continuous variables or as an absolute frequency 
and percentage frequency for categorical variables. 
The data management and the statistical analysis were 
conducted using Statistical Package for the Social Sciences 
(SPSS) version 15.
RESULTS
Thirty-six physicians responded to the survey: 56% 
(20 physicians) were ICU specialists with > 5 years of 
experience in the ICU; 33% (12) were specialists in 
infectious diseases; and 3% (1) were ICU specialists with 
< 5 years of experience. Less than 10% (3 physicians) 
identified with another specialty: anesthesia, internal 
medicine or cardiology (Table 1). Seventeen physicians 
(47%) worked in an academic institution; 31 of 
36 (86%) practiced in a medical-surgical ICU. The 
provenance was primarily from Brazil (25 physicians; 
69%), followed by Venezuela (4; 11%), Mexico (2; 6%) 
and Chile (2; 6%).
In the two clinical cases, a total of 135 antibiotics were 
detailed (Tables 2 and 3): 68 in the first case and 67 in the 
second. In case 1, the most employed group of antibiotics 
was beta-lactams (29 of 68 prescriptions; 42.7%), with 
ceftriaxone being prescribed in 29.4% of cases. Macrolides 
(clarithromycin and azithromycin) were indicated in 19 
of 68 prescriptions (27.9%), and quinolones (levofloxacin 
and moxifloxacin) were indicated in 8 (11.8%). The most 
prescribed antibiotic patterns were as follows (Figure 1): 
ceftriaxone and clarithromycin (9 patients of 36; 25.0%), 
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Table 1 - Information from the 36 survey participants
Frequency
Specialization
Intensive care for more than 5 years 20 (55.6)
Intensive care for less than 5 years 1 (2.8)
Infectious diseases 12 (33.3)








Did not answer 7 (19.4)
Type of ICU
Mixed medical-surgical 31 (86.1)
Medical 2 (5.6)
Surgical 0
Did not answer 3 (8.3)
Level of care
Third level 27 (75.0)
Second level 1 (2.8)






Did not answer 3 (8.3)
Results are expressed as the absolute values and percentages: n (%). ICU - intensive care unit.
Table 2 - Antibiotic prescription, dose and duration in the case of community-acquired pneumonia
Antibiotic N indications Dose*









Ceftriaxone 20/68 (29.4) 2.0 (2.0 - 3.5) 19/20 (95.0) 0/20 (0) 17/20 (85.0) 3/20 (15.0)
Cefepime 5/68 (7.4) 6.0 (5.0 - 6.0) 4/5 (80.0) 0/5 (0) 3/5 (60.0) 2/5 (40.0)
Meropenem 4/68 (5.9) 3.0 (1.9 - 3.0) 3/4 (75.0) 0/4 (0) 3/4 (75.0) 1/4 (25.0)
Macrolides 19/68 (27.9)
Clarithromycin 10/68 (14.7) 1.0 (0.9 - 1.0) 8/10 (80.0) 0/10 (0) 8/10 (80.0) 2/10 (20.0)
Azithromycin 9/68 (13.2) 0.5 (0.5 - 1.0) 9/9 (100) 0/9 (0) 7/9 (77.8) 2/9 (22.2)
Quinolones 8/68 (11.8)
Levofloxacin 4/68 (5.9) 0.8 (0.6 - 0.8) 3/4 (75.0) 0/4 (0) 4/4 (100) 0/4 (0)
Moxifloxacin 4/68 (5.9) 0.4 (0.4 - 1.3) 4/4 (100) 0/4 (0) 4/4 (100) 0/4 (0)
Glycopeptides 4/68 (5.9)
Vancomycin 4/68 (5.9) 2.0 (2.0 - 2.0) 4/4 (100) 0/4 (0) 3/4 (75.0) 1/4 (25.0)
Others 8/68 (11.8)
Results are expressed as the absolute values and percentages: n (%); * result is expressed as the median and interquartile range.
ceftriaxone/cefotaxime and azithromycin (5 patients; 
13.9%), and ceftriaxone and levofloxacin/moxifloxacin (5; 
13.9%). In 32 of 36 cases (88.9%), combined treatment 
was indicated. Active anti-Pseudomonas treatment was 
prescribed in 15 of 36 patients (41.7%) while treatment 
for methicillin-resistant Staphylococcus aureus (MRSA) was 
indicated in 6 of 36 patients (16.7%).
Treatment was adequate according to the 
IDSA/ATS recommendations in 11 of 36 prescriptions 
(30.6%) (Table 4). The causes of non-compliance were 
monotherapy (4 of 25; 16.0%); unnecessary coverage 
for P. aeruginosa/MRSA in 10 prescriptions (40.0%); 
and administration of double antibiotic treatment 
with medications that were not indicated in 11 of 25 
prescriptions (44.0%). The most employed antibiotics 
were clarithromycin (10 prescriptions), clindamycin (1 
prescription) and amoxicillin clavulanic (1 prescription).
In case 2, the most indicated antibiotics were 
meropenem (20 prescriptions of 67; 29.9%), 
vancomycin (14; 20.9%), linezolid (14; 20.9%) and 
piperacillin-tazobactam (13; 19.4%) (Table 3). The 
most highly employed regimens are shown in figure 2: 
meropenem and linezolid (10 patients of 36; 27.8%), 
meropenem and vancomycin (9 patients of 36; 25.0%), 
piperacillin-tazobactam and linezolid (5 of 36; 13.9%) 
and piperacillin-tazobactam in monotherapy (5; 13.9%). 
Monotherapy was indicated in 5 of 36 patients (13.9%), 
and combined antibiotic treatment was prescribed in 
the 31 remaining patients (86.1%). In all cases, active 
treatment was indicated for P. aeruginosa. Active treatment 
for MRSA was indicated in 30 of 36 patients (83.3%).
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Table 3 - Antibiotic prescription, dose and duration in the case of nosocomial pneumonia
Antibiotic N indications Dose*









Meropenem 20/67 (29.9) 3.0 (3.0 - 6.0) 18/20 (90.0) 0/20 (0) 13/20 (65.0) 7/20 (35.0)
Piperacillin-tazobactam 13/67 (19.4) 18.0 (15.8 - 18.0) 12/13 (92.3) 0/13 (0) 10/13 (76.9) 3/13 (23.1)
Glycopeptides 14/67 (20.9)
Vancomycin 14/67 (20.9) 2.0 (2.0 - 2.0) 14/14 (100) 0/14 (0) 12/14 (85.7) 2/14 (14.3)
Oxazolidinones 14/67 (20.9)
Linezolid 14/67 (20.9) 1.2 (1.2 - 1.2) 14/14 (100) 0/14 (0) 9/14 (64.3) 5/14 (35.7)
Others 6/67 (8.9)
Results are expressed as the absolute values and percentages: n (%); * result is expressed as the median and interquartile range.
Table 4 - Fulfillment of Infectious Disease Society of America/American Thoracic Society recommendations and reasons for non-adherence
Clinical case Adherence to recommendations Case 1 - Reasons for non-adherence Case 2 - Reasons for non-adherence










11/36 (30.6) 25/36 (69.4) 4/25 (16.0) 10/25 (40.0) 11/25 (44.0) ---
Nosocomial pneumonia 
Case 2
1/36 (2.8) 35/36 (97.2) --- 5/35 (14.3) 30/35 (85.7)
Results are expressed as the absolute values and percentages: n (%). multiR - multi-resistant; AB - antibiotic; PA - Pseudomonas aeruginosa.
Figure 1 - Antibiotic regimens most frequently indicated in the case of 
community-acquired pneumonia.
Figure 2 - Antibiotic regimens most frequently indicated in the case of nosocomial 
pneumonia.
Adherence to the IDSA/ATS indications occurred in 
3% of patients (1 patient of 36, with meropenem and 
levofloxacin being indicated) (Table 4). The causes of 
non-compliance were monotherapy in 5 prescriptions 
of 35 (14.3%) and lack of double antibiotic coverage 
for P. aeruginosa in 30 indications of 35 (85.7%). If 
the administration of only one active antibiotic for 
P. aeruginosa had been considered adequate, as indicated 
in other recommendations,(16) whether it was paired with 
an active antibiotic for MRSA, the rate of appropriate 
treatment would have been 100%.
DISCUSSION
The most noteworthy conclusion from this study 
population is the limited adherence to IDSA/ATS 
recommendations when prescribing empirical antibiotics 
for severe pneumonia. In line with the results obtained 
from studies conducted on other continents,(11-14) this 
conclusion carries strong implications because a low 
adherence to therapeutic recommendations is associated 
with greater morbidity and mortality as well as with an 
increase in health costs.(4,8,17)
Studies conducted in Europe report adherence rates of 
between 20 and 100%. The proposed causes of non-adherence 
were differences between the patient being treated and 
the condition described in the guidelines, the presence of 
kidney or liver failure, the unavailability or excessive costs of 
specific antibiotics, and differences between local flora and 
international recommendations.(11,12,18)
In the case of community-acquired pneumonia, 
treatment was adequate in 31% of patients (11 of 36). 
Although the therapeutic guidelines recommend initiation 
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and clarithromycin are close to the maximum values of 
the minimum inhibitory concentration for the important 
pathogens, their rapid collection in the intra-cellular 
compartment and their slow liberation make them efficient 
for this purpose. This phenomenon is more marked with 
azithromycin due to a more prolonged antimicrobial 
exposure as a result of its post-antibiotic effect, which 
allows 3-5-day treatment cycles to be sufficient.(33) 
However, a limitation of azithromycin is its high intra-cell/
interstitial concentration quotient, which could justify its 
bad behavior against extracellular microorganisms.(34)
In the case of nosocomial pneumonia, an adherence 
of only 3% of the recommendations is noteworthy, 
with the only adequate regimen being meropenem and 
levofloxacin. The IDSA/ATS recommendations indicate 
using a beta-lactam paired with an aminoglycoside or an 
active quinolone for P. aeruginosa. In the case of MRSA 
infection risk, its coverage is indicated. However, in the 
present case, it was not considered necessary to provide 
coverage for MRSA, although providing coverage for this 
infection was not classified as inadequate.
Of the 35 inadequate regimens, monotherapy was 
indicated in five cases, always ensuring Pseudomonas 
aeruginosa coverage; on the other hand, combined therapy 
was indicated in 30 cases. In all the 30 cases of combined 
therapy, at least one antibiotic was active against 
P. aeruginosa and another was active against MRSA. 
The IDSA/ATS recommendations suggest initiating a 
double antipseudomonal treatment with the purpose of 
minimizing the risk of not covering the pathogen due to 
an antibiotic resistance pattern.
Garnacho-Montero et al. addressed monotherapy 
versus bitherapy in ventilator-associated pneumonia due 
to P. aeruginosa. In their conclusions, they confirm that 
combination treatment reduces the risk of inadequate 
empirical treatment. However, there were no differences 
in mortality between monotherapy and combination 
therapy. In addition, the cases of Pseudomonas with reduced 
sensitivity to carbapenems that received 6g of meropenem 
per day did not increase mortality.(35) In this sense, in a 
hospital institution at which the resistance of P. aeruginosa to 
carbapenem is not a problem, the use of monotherapy with 
high-dose of meropenem could be an acceptable option. 
Similarly, the utilization of a beta-lactam in monotherapy 
in an environment with very low risk of antibiotic resistance 
could be an adequate option. Despite this, the lack of 
randomized clinical trials does not allow this finding to 
be generalized. To support this assertion, according to the 
European recommendations,(16) a patient with nosocomial 
pneumonia that is acquired within the first four days of 
admittance should receive only one antibiotic. Considering 
of broad-spectrum treatment in high-suspect cases of 
multi-resistant pathogens, this was not considered a 
correct option because in the setting presented, the patient 
did not have risk factors for nosocomial pathogens. There 
were various causes of non-adherence. Prescription of 
monotherapy (16%) was a reason for non-adherence, 
as various studies have shown that in patients with 
respiratory shock, combination antibiotic treatment 
reduces mortality.(19-21) In addition, a clinical trial 
conducted in patients with severe community-acquired 
pneumonia concluded that mortality is higher in 
patients who received fluoroquinolone versus bitherapy, 
although statistical significance was not achieved.(22) In 
general, every patient admitted to the ICU with severe 
CAP should receive treatment for pneumococcus and 
Legionella pneumophila, using an anti-pneumococcal 
bactericide, with the first option being a beta-lactam and 
an active agent for Legionella spp., such as levofloxacin or 
azithromycin.(23,24)
Another cause for the lack of adherence was the 
extensive coverage for P. aeruginosa and MRSA. A total of 
40% of patients received active multi-resistant treatment. 
It has been previously shown that the prevalence of 
multi-resistant organisms and MRSA is higher in Latin 
America than in other countries.(25,26) However, the extensive 
use of broad-spectrum antibiotics leads to an increase in the 
appearance of opportunistic pathogens.(27-29) Because of this 
fact, it is essential to monitor the local bacterial flora.(9)
The third reason for the lack of adherence was 
the prescription of antibiotics not indicated in the 
recommendations. A total of 44% of patients received 
treatment with a non-antipseudomonal cephalosporin in 
addition to clarithromycin. In the 2003 IDSA guidelines, the 
association of a beta-lactam with a macrolide (erythromycin, 
clarithromycin or azithromycin) is indicated,(30) while in the 
latest update,(9) azithromycin is recommended.
The utility of macrolides has been essential in the 
treatment of pneumonia, due to their activity against 
pneumococcus and atypical pathogens.(31) The utility of 
erythromycin, the first macrolide available, has diminished 
due to its gastrointestinal adverse effects, lack of efficacy 
against Haemophilus influenzae and the emergence of 
pneumococcus resistance.
The main advantages of azithromycin and 
clarithromycin compared to erythromycin are less 
adverse effects and greater tissue penetration, stability 
against gastric pH, greater half-life, few pharmacological 
interactions and a greater post-antibiotic effect. The tissue 
concentration of azithromycin can be between 10 and 100 
times greater than that obtained in blood.(32) Although 
the maximum concentrations reached by azithromycin 
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the administration of an anti P. aeruginosa to be adequate in 
our population, the rate of adherence would be 100%.
The present analysis has several limitations. Most 
importantly, this is a clinical survey based on fictitious 
cases, and therefore, the data do not come from real clinical 
practice. However, the high rate of intensive care physicians 
or infectious disease specialists with extensive work 
experience in the ICU in a third-level university setting 
confers a high validity and reliability to the study results.
Another important limitation is that the majority of those 
surveyed came from Brazil, and there was not, therefore, a 
proportional representation of the different Latin American 
countries. An analysis was conducted to compare the responses 
of physicians from and not from Brazil, and no significant 
differences were obtained. In addition, the physicians came 
from different cities in Brazil and from other Latin American 
countries. Due to confidentiality considerations and to not 
bias the responses, the authors decided not to communicate 
the survey participants’ cities of origin. Finally, a higher 
number of survey participants may have supplied more 
representative data. The conduction of a similar study with 
a greater sample size could be useful for confirming the 
findings obtained and guaranteeing a higher reproducibility 
and representation of all Latin American states.
CONCLUSION
In the present survey on empirical antibiotic 
prescription in severe pneumonia, which was conducted 
using a small sample of physicians from Latin America, 
adherence to therapeutic Infectious Disease Society 
of America/American Thoracic Society guidelines was 
relatively low. However, these findings were in line with 
results from studies conducted on other continents. In 
the case of community-acquired pneumonia, the causes of 
non-adherence were the high indication of monotherapy, 
coverage for multi-resistant pathogens made when it was 
not indicated and the employment of antibiotics that were 
not indicated. In the case of nosocomial pneumonia, the 
most important cause of non-compliance was the use of 
only one active antibiotic for P. aeruginosa.
Objetivo: Valorar tasa de adherencia y causas de no adhe-
rencia a las guías terapéuticas internacionales para la prescripci-
ón antibiótica empírica en la neumonía grave en Latinoamérica.
Métodos: Encuesta clínica realizada a 36 médicos de Latino-
américa donde se pedía indicar el tratamiento empírico en 2 ca-
sos clínicos ficticios de pacientes con infección respiratoria grave: 
neumonía adquirida en la comunidad y neumonía nosocomial.
Resultados: En el caso de la neumonía comunitaria el tra-
tamiento fue adecuado en el 30,6% de las prescripciones. Las 
causas de no adherencia fueron monoterapia (16,0%), cober-
tura no indicada para multirresistentes (4,0%) y empleo de an-
tibióticos con espectro inadecuado (44,0%). En el caso de la 
neumonía nosocomial el cumplimiento de las guías terapéuticas 
Infectious Disease Society of America/American Thoracic Society fue 
del 2,8%. Las causas de falta de adherencia fueron monotera-
pia (14,3%) y la falta de doble tratamiento antibiótico frente a 
Pseudomonas aeruginosa (85,7%). En caso de considerar correcta 
la monoterapia con actividad frente a P. aeruginosa, el tratamien-
to sería adecuado en el 100% de los casos.
Conclusión: En la neumonía comunitaria la adherencia a 
las guías terapéuticas Infectious Disease Society of America/Ame-
rican Thoracic Society fue del 30,6%; la causa más frecuente de 
incumplimiento fue el uso de monoterapia. La adherencia en 
el caso de la neumonía nosocomial fue del 2,8% y la causa más 
importante de incumplimiento fue la falta de doble tratamiento 
frente a P. aeruginosa, considerando adecuada monoterapia con 
actividad frente a P. aeruginosa la adherencia sería del 100%.
RESUMEN
Descriptores: Infecciones comunitarias adquiridas/quimiote-
rapia; Neumonía asociada al ventilador/quimioterapia; Antibac-
terianos/uso terapéutico; Adhesión a las directivas anticipadas
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